ghana ndp 2014 review process.ppt(nmp) is the policy document providing guidance to the...

WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014

Ghana National Medicine

Policy Review 2014

The Process

4th November 2014

George Hedidor

B.Pharm, MPH

Prin. Pharmacist. Ministry of Health, Ghana


Outline

�Introduction

�Review of the 2004 NMP

�Aims of the NMP

�Review Process

• Assessment of 2004 Document

• Stakeholder engagements

• Components of NMP

• Matters Arising from Stakeholder engagements

�Current status

�Acknowledgement


Introduction

• The NDP to be renamed National Medicines Policy

(NMP) is the policy document providing guidance to

the pharmaceutical sector in Ghana

– 1st edition 1999

– 2nd edition 2004

– 3rd edition 2014 (have been under review since October

2013)

• It represents decisions based on the best current

evidence

• the consensus opinion of all stakeholders

• the general direction of governance on

pharmaceuticals and other related health

technologies


Revision of 2004 NMP

� Revision has been necessitated by the need

to:

• strengthen pharmaceutical systems as a key

component of health systems to meet the ever-

changing health needs of the population

• sustain the gains made in ensuring financial

access to medicines for the poor and vulnerable

• develop local pharmaceutical industry,

• strengthen the regulation of pharmaceuticals in

Ghana


Aim of the new NMP

�The new medicines policy aims to actualize the

commitment of the Government of Ghana towards

the goal of ensuring universal access to affordable

essential medicines of assured quality for all

persons living in Ghana, as well as their responsible

use by health professionals and consumers.

�To provide direction and guidance for all

stakeholders in the pharmaceutical sector towards

one common goal.


The Review Process

� The NMP review process is deemed as equally important

as the output of the process (the policy itself)

Based on developments at the national and global levels

and reasons discussed above

•Independent assessment of the pharmaceutical sector in

2013 based on the 2004 NMP by WHO consultant, and

through several stakeholder consultations

�The basic aim of the assessment was to determine the level

of implementation of the 2004 policy

�Propose policy directions for 2014 - 2020


Assessment of Medicines Policy

Cre

dit

: W

HO

Ass

ess

me

nt

of

the

20

04

Po

licy

in

20

13

7

GREEN (ON TRACK): Objectives achieved and/or policy component is on track

(middle) ORANGE (AT RISK): The objective is partially achieved and/or mechanisms are partly in

place, but more effort is needed to achieve the policy objective;

(top) RED (STAND-STILL): The activity has not started


Process continues

• Dissemination of results of assessment to key

stakeholders

• The Minister of Health inaugurated a Technical

Working Group (TWG) to revised the policy

• Consider the assessment report and policy

recommendations

• Revise the 2004 NMP

• Draft a new NMP


NMP Technical Working Group (TWG)Organization

School of Public Health, University of Ghana

Community Practice Pharmacist Association/Pharmaceutical Society of Ghana

Ghana National Drugs Programme, Ministry of Health

Pharmacy Council

Policy Planning Monitoring and Evaluation, Ministry of Health

WHO Country Office for Ghana

Society of Private Medical and Dental Practitioners

National Drug Information Resource Centre

Attorney General’s Office, Ministry of Justice

Medicines Transparency Alliance

Pharmaceutical Manufacturers Association of Ghana

Ghana Medical Association

UNIDO desk/Ministry of Trade and Industry

Ministry of Health

Food and Drug Authority

Traditional Medicines Directorate, Ministry of Health

National Health Insurance Authority

Procurement and Supply Directorate, Ministry of Health


-------

• TWG worked in sub-committees based on different themes in

the document with co-opted members where appropriate

(e.g. NHIA, FDA, etc.)

• Developed a template for report for each sub group

• Retreat for TWG members to collate all responses and

consider the proposed policy statement

• The TWG has worked systematically based on the best

evidence to develop a revised 2014 DRAFT NMP.


1. Broad Policy Area: [eg. Selection, procurement etc.] Comments

Response

1. Policy statement:

[The policy statement as it should appear in the policy document]

Comments

1. Implications of this policy statement, Financial/Economic/etc.

[NB: e.g. If you indicate that a policy has Economic implications, you must describe what that

implication is]

Comments

Response

1. Actions:

[Describe the Activities to be carried out in order to achieve the policy statement above]

Comments

Response

1. Justification(s):

[Indicate the justification for the activities indicated above. Also indicate whether it’s a short,

medium or long term activity]

Comments

Response

1. Indicators:

[List/indicate measurable Monitoring Indicator(s) for this policy statement]

Comments

Response

1. Please include possible data sources for the indicator above Comments

Response

1. Communication plan Comments

Response

9. Any other information, relating to this policy statement Comments

NB: The deadline for the submission of this work is 16th April 2014.

Working template for the Formulation of Policy Statements for the National Drug Policy Review 2013/2014GUIDEPlease note that sub-groups are to fill one form/template per policy statement to be included in the revised policy. The spaces provided could be extended to accommodate more information. Any other information not captured in this template can be provided under item 9. The section for comments is to capture any further details that give clarity on the specific item being described.


Stakeholder engagement workshop

�Stakeholder engagement

• To ensure that all relevant stakeholders are involved in

charting the course of the management of

pharmaceuticals in the years ahead

�Advocacy and Information sharing

• To ensure that all relevant stakeholders are ‘on board’

� Consensus building

• To build consensus on some outstanding aspects of the

policy

�Stakeholder consultation

• To harness the views of stakeholders on aspects of the

revised policy


Key components of the NMP

• Old components

– Selection of essential medicines and health technologies

– Financing

– Procurement medicines and other health technologies

– Quality assurance

– Local Manufacture

– Disposal of medicines

– Rational medicine use

– Global trade in pharmaceuticals and health technologies

– Emerging Diseases and Pharmaceuticals

– Human Resource Development for Drug Management

– Traditional Medicinal Products

– Research and development

– National Medicine Policy implementation


Key components of the NMP• New components

• Health Technology Assessments

• Transparency and Accountability

• Governance (Good)

• Pricing

• Disposal of Medicines

• Suggested sections/statements on:

• AMR policy, Bioequivalence center

• New additions to strengthen policy implementation

• A costed Implementation Plan with defined roles, targets, SMART

objectives and indicators

• The implementation plan would also have:

• An advocacy and communications strategy

• A monitoring and evaluation framework


Critical issues during stakeholder

consultations

� Policy on procurement

• Important policy interventions in procurement that ensures

efficiency and value for money. This has implications on

sustainability of reimbursements under NHIA

�Policy on pricing

• The expansion of the scope of the current section of draft policy on

pricing into a dedicated section as a pricing policy for Ghana

�Policy on Rational Use of Medicines

• policy to promote rational use of medicines in the community

• Issues around dispensing doctors and prescribing pharmacists

(separation of services)

�Strengthening of FDA, products, manufacturing,

wholesalers


Critical issues during stakeholder

consultations

�Private sector involvement

• Strengthening private sector role in all relevant aspects of

the policy

�Implementation

• Engagement of implementing stakeholders to formulate

detailed activities, budgets and specific timelines; for

Policy Implementation Plan

�Prioritizing areas in the revised policy for

immediate action

• In the context of resource constrains, which aspects of the

revised policy must be addressed immediately as a priority


Current status of the new NMP

�Inputs from stakeholders have been considered

by TWG to finalize the policy

�An implementation, advocacy and communication

plan, as well as an M and E framework has also been

drafted

�Process to engage:

• The Minister of Health, and other relevant Ministers,

National Development Planning Commission as well as

the Parliamentary Select Committee on Health for

Cabinet endorsement and implementation


Acknowledgement

� Appreciation to the following:

• Director of Pharmaceutical Services (Martha Gyansa-

Lutterodt) for providing leadership

• Ghana National Drugs Programme

• Ministry of Health, Ghana

• Medicines Transparency Alliance (MeTA) Ghana

• WHO Country Office

• EU/ACP/WHO Renewed Partnership for strengthening

pharmaceutical systems

• TBS participants


Stakeholder forum pictures


Thank You

Merci

ghana ndp 2014 review process.ppt(nmp) is the policy document providing guidance to the...

Documents